Aspirin/atenolol/hydrochlorothiazide/ramipril/simvastatin - Cadila Pharmaceuticals
Alternative Names: Polycap; Polypill - Cadila Pharmaceuticals; QuintapillLatest Information Update: 09 Jan 2025
At a glance
- Originator Cadila Pharmaceuticals
- Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Benzothiadiazines; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Platelet aggregation inhibitors; Thiazide diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Cardiovascular disorders; Coronary disorders; Stroke
Most Recent Events
- 09 Jan 2025 No development reported - Phase-III for Cardiovascular disorders (Prevention) in Bangladesh, Malaysia, Philippines, Tanzania, Colombia, Tunisia, Canada (PO)
- 30 Aug 2021 Cadila Pharnmaceuticals and Population Health Research Institute completes a Phase-III TIPS-3 trial in Cardiovascular disorders (Prevention) in Philippines, Tunisia, Colombia, Canada, Malaysia, Bangladesh, India and Tanzania (PO) (NCT01646437)
- 04 Feb 2019 Chemical structure information added